Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/humrep/14.9.2183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Triggering final follicular maturation for IVF cycles.
Reprod Biol Endocrinol
January 2025
Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, 52621, Israel.
As part of a conventional controlled ovarian hyperstimulation (COH) regimen, final follicular maturation is usually triggered by a single bolus dose of human chorionic gonadotropin (hCG). COH, which combines GnRH antagonist co-treatment with GnRH agonist(GnRHa) trigger, is often used in attempts to eliminate severe early ovarian hyperstimulation syndrome and to improve oocyte/embryo yield and quality. Recently, the combination of GnRHa, with hCG trigger has also been implemented into clinical practice.
View Article and Find Full Text PDFThe first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
We assessed the safety and efficacy of rhFSH-CTP, a novel long-acting FSH agent, in controlled ovarian hyperstimulation for patients undergoing ART. A multi-center, open-label, randomized, positive-control, non-inferiority clinical trial was conducted. The study consisted of a phase III randomized design, with a 1:1 ratio favoring the rhFSH-CTP group over the control group.
View Article and Find Full Text PDFPrevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline.
Hum Fertil (Camb)
December 2025
Developmental Biology and Medicine, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.
This British Fertility Society (BFS) Policy and Practice guideline aims to support clinicians in preventing ovarian hyperstimulation syndrome (OHSS) in patients undergoing gonadotropin ovarian stimulation. A systematic literature search of the medical databases was performed. The Guideline Development Group (GDG) identified the risk factors of OHSS before and during ovarian stimulation.
View Article and Find Full Text PDFSafety and effectiveness of dual trigger (GnRH agonist + HCG) versus HCG alone in patients with high ovarian response.
Am J Transl Res
November 2024
Reproductive Medicine Center, Hunan Provincial Maternal and Child Healthcare Hospital Changsha 410008, Hunan, China.
Objective: To compare the safety and effectiveness between long-term GnRH agonist plus HCG (dual trigger) and HCG trigger alone in high ovarian responders.
Methods: A retrospective study was conducted on clinical data from 314 cases of high ovarian response who underwent in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment at Hunan Provincial Maternal and Child Healthcare Hospital from July 2018 to January 2023. Participants were divided into two groups based on their triggering regimen: the Combined treatment group (GnRH agonist + HCG) and the HCG group (HCG alone).
Outcomes of subsequent IVF cycles among women with PCOS after the first unstimulated IVM treatment: a single-center matched retrospective case-control study.
J Matern Fetal Neonatal Med
December 2024
Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
Objective: maturation (IVM) is an advanced technique and an alternative to conventional fertilization (IVF). It is safe, effective, and cost-effective in patients with polycystic ovary syndrome (PCOS). However, no clinical guidelines state that IVM could work without compromised pregnancy outcomes in patients with PCOS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!